Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GAVE_YOU_$ETST__AT_.40_NOW_$2_NOW__CALLING__$NMUS!!!
GAVE_YOU_$ETST__AT_.40_NOW_$2_NOW__CALLING__$NMUS!!!
CALLED_$ETST__AT_.40cent_For_500%_NOW__CALLING__$NMUS!!!
CALLED_$ETST__AT_.40cent_For_500%_NOW__CALLING__$NMUS!!!
$NMUS ON_WATCH_FLOAT_=_5,005,713_BREAKOUT_WILL_HAPPEN@_.50_CENTS
$NMUS ON_ALERT_TODAY_FLOAT_IS_5,005,713_BREAKOUT_AT_.50_CENTS
$NMUS ON_ALERT_TODAY_FLOAT_IS_5,005,713_BREAKOUT_AT_.50_CENTS
$NMUS ON_HIGH_ALERT_FLOAT_IS_5,005,713_BREAKOUT_WILL_OCCUR_AT_.50_CENTS
$NMUS ON_HIGH_ALERT_FLOAT_IS_5,005,713_BREAKOUT_WILL_OCCUR_AT_.50_CENTS
$NMUS ON_HIGH_ALERT_FLOAT_IS_5,005,713_FREELY_TRADING
$NMUS ON_HIGH_ALERT_FLOAT_IS_5,005,713_FREELY_TRADING
$NMUS FLOAT_REMAINS_UNCHANGED_AT_5,005,713_FREELY_TRADING
$NMUS FLOAT_REMAINS_UNCHANGED_AT_5,005,713_FREELY_TRADING
$NNUS _5_MILLION_SHARE_FLOAT_SIMILIAR_TO_ $ETST
Please Post on $NMUS MESSAGE BOARD AS WELL!! YOUR VERY HELPFUL!
Please_UPDATE_$NMUS_CHARTS_ON_THE_BOARDS!
$NMUS GET_READY_SELLERS_ARE_OUT_OF_SHARES!_WITH_VOLUME_IT_WILL_ROCKET_HIGHER!
$NMUS _SELLERS_ARE_OUT_OF_SHARES!_WITH_VOLUME_IT_WILL_ROCKET_HIGHER!
$NMUS_SELLERS_ARE_OUT_OF_SHARES!_WITH_VOLUME_IT_WILL_ROCKET_HIGHER!
$NMUS_SELLERS_ARE_OUT_OF_SHARES!_WITH_VOLUME_IT_WILL_ROCKET_HIGHER!
LISTEN_UP_Called $ETST at .40, $NMUS ON HIGH ALERT! CHARTS READY!
Called $ETST at .40, $NMUS ON HIGH ALERT! CHARTS READY!
Called $ETST at .40, $NMUS ON HIGH ALERT! CHARTS READY!
$NMUS MAJOR NEWS COMING!_CONFIDENTIAL_TREATMENT_ORDER JUST_FILED, IS LIKELY SOME BREAKTHROUGH TECHNOLOGY / PATENTS / STRATEGIC COLLABORATIONS / CONTRACTS ETC. (Likely Key Patents in Collaboration with the University of Mississippi)
https://twitter.com/MOMOSTOCKTRADES/status/828771593870512133
Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
http://m.marketwired.com/press-release/nemus-enters-into-research-agreement-with-university-mississippi-develop-cannabinoid-otcqb-nmus-2084037.htm
MAJOR PATENT FILINGS ARE THE MOST COMMON REASON FOR Confidential Treatment Orders
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Nemus Bioscience, Inc.
File No. 000-55136 - CF#34642
https://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11826936
CHARTS SETTING UP FOR AN EXPLOSIVE MOVE UP!
https://www.barchart.com/stocks/quotes/NMUS/technical-chart#/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(50);SMA(10);SMA(5)&sym=NMUS&grid=1&height=500&studyheight=100
Explosive Chart Setup, $NMUS Daily and Weekly Ichimoku Chart
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128465998
$NMUS BIG NEWS COMING! CONFIDENTIAL TREATMENT ORDER JUST FILED, IS LIKELY SOME BREAKTHROUGH TECHNOLOGY / PATENTS / STRATEGIC COLLABORATIONS / CONTRACTS ETC. (Likely Key Patents in Collaboration with the University of Mississippi)
https://twitter.com/MOMOSTOCKTRADES/status/828771593870512133
Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
http://m.marketwired.com/press-release/nemus-enters-into-research-agreement-with-university-mississippi-develop-cannabinoid-otcqb-nmus-2084037.htm
MAJOR PATENT FILINGS ARE THE MOST COMMON REASON FOR Confidential Treatment Orders
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Nemus Bioscience, Inc.
File No. 000-55136 - CF#34642
https://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11826936
CHARTS SETTING UP FOR AN EXPLOSIVE MOVE UP!
https://www.barchart.com/stocks/quotes/NMUS/technical-chart#/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(50);SMA(10);SMA(5)&sym=NMUS&grid=1&height=500&studyheight=100
$NMUS BIG NEWS COMING! CONFIDENTIAL_TREATMENT_ORDER JUST_FILED, IS LIKELY SOME BREAKTHROUGH TECHNOLOGY / PATENTS / STRATEGIC COLLABORATIONS / CONTRACTS ETC. (Likely Key Patents in Collaboration with the University of Mississippi)
https://twitter.com/MOMOSTOCKTRADES/status/828771593870512133
Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
http://m.marketwired.com/press-release/nemus-enters-into-research-agreement-with-university-mississippi-develop-cannabinoid-otcqb-nmus-2084037.htm
MAJOR PATENT FILINGS ARE THE MOST COMMON REASON FOR Confidential Treatment Orders
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Nemus Bioscience, Inc.
File No. 000-55136 - CF#34642
https://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11826936
CHARTS SETTING UP FOR AN EXPLOSIVE MOVE UP!
https://www.barchart.com/stocks/quotes/NMUS/technical-chart#/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(50);SMA(10);SMA(5)&sym=NMUS&grid=1&height=500&studyheight=100
Greengro Technologies, Inc. Launches Cannabis Genetics Breeding Initiative
Creates New Division Called GenoBreeding to Improve Cannabis Strains
ANAHEIM, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Greengro Technologies, Inc. (OTC:GRNH), a world-class provider of eco-friendly green technologies, today launched a new internal company division called GenoBreeding that will direct a Greengro initiative to bring to the market cutting edge cannabis varieties through the application of modern plant breeding technologies.
This initiative from Greengro is in keeping with the cannabis industry’s increasing reliance on genetics – heredity and the variation of inherited characteristic in plants – to help growers create better, more powerful and sometimes personalized commercial cannabis strains that share desirable inherited characteristics.
“This initiative includes the use of conventional and modern plant breeding techniques to develop high quality cannabis varieties for medical use,” said Greengro CEO James Haas.
Greengro is working with a team of specialized plant scientists and geneticists to develop cannabis varieties that possess improved levels of key compositional traits (e.g., THC and CBD) by using innovative breeding technologies, according to Haas, who said that Greengro has had its cannabis genetics program in development for a number of years.
Greengro’s GenoBreeding group is focused on developing breeding tools such as molecular markers to enable breeding decisions and processes to achieve top-tier plant performance in a sustainable manner.
“Our collaboration through this initiative with leading scientists enables us to utilize proven crop breeding techniques in the indoor production of cannabis, while at the same time modernizing Greengro’s existing efforts to produce original products for California’s cannabis market,” said Haas, who indicated that the GenoBreeding division will eventually be spun off into its own company.
“We’re developing market leading elite cannabis genetics with innovative breeding solutions,” explained Haas.
Greengro’s GenoBreeding initiative combines elite cannabis genetics with state-of-the-art plant breeding methods to maximize yields and expression of desired traits. Key elements in the breeding program include:
Development of molecular markers for desired traits and implementation of marker-assisted selection to reduce breeding cycle time.
Application of genomic systems to enable breeding decisions and processes to achieve sustainable, top-tier plant performance.
The goal of Greengro’s GenoBreeding initiative in using applied genetics in cannabis production is to promote stability and predictability in hybridized strains. Stability refers to minimizing variability and maximizing predictability found in the offspring of parent plant generations.
Genetics is helping growers create better, more powerful and sometimes personalized commercial cannabis strains.
This process involves the cannabis genome (the complete set of genes and genetic material present in the plant), genotype (the plant's complete heritable genetic identity), and phenotype (the set of a strain’s expressed, observable characteristics resulting from the interaction of its genotype with the environment).
Variability, a consequence of strain genetic instability, refers to the range of different phenotypes that will express when hybridizing two different plant strains. Desirable predictability refers to the expected distribution ratio of a plant’s different phenotypes expressed as a unique strain.
About Greengro Technologies
Greengro Technologies is a national leader in both indoor and outdoor aquaponic and hydroponic systems and grow rooms, with specific domain expertise in agricultural science systems serving both the consumer and commercial farming markets. The company's customers include restaurants, community gardens, and small- and large-scale commercial clients. For more up to date info like our Facebook page at https://www.facebook.com/GreengroTechnologiesInc?ref=hl.
$NMUS and $ETST Blasting Off!
$NMUS and $ETST ON HIGH ALERT!
$NMUS and $ETST #BreakoutAlert !
$NMUS and $ETST Breakouts !
$NMUS and $ETST Running!
Gave $ETST at .40cent,$NMUS Next 300%+ Potential Gainer! UNDISCOVERED CANNANABOID BIOTECH CO
Gave $ETST at .40cent,$NMUS Next 300%+ Potential Gainer! UNDISCOVERED CANNANABOID BIOTECH CO
HUGE News Out!! YahooFINANCE Share
Yahoo Finance All Markets Summit
Earth Science Tech Announces New Wholly Owned Subsidiary, Cannabis Therapeutics Inc., to Develop & Launch its Cannabis Cannabinoid-Based Drugs & Nutraceuticals Using its Cannabinoid-Cannabidiol (CBD) Patent, IP and Technology
GlobeNewswire•February 6, 2017
Hollywood, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is pleased to announce its new wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals.
Cannabis Therapeutics, Inc. will begin by inventing & launching Two (2) New Cannabinoid-based Pharmaceutical drugs and Three (3) New Advanced Cannabinoid-based Nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, Invention, Technology and future Technology. ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.
Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid (phytocannabinoids and synthetic cannabinoids) research and development for a broad line of cannabis cannabinoid-based therapeutic pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company has appointed Dr. Michel Aube as the CEO and Nickolas Tabraue as the President of Cannabis Therapeutics, Inc.
CEO of Cannabis Therapeutics, Inc., Dr. Michel Aube, stated, “I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). We look to announce later this week a New Scientific Advisory Board which will include myself, Dr. Michel Aube, as the Chairman of the Advisory board to Cannabis Therapeutics, Inc. as well as other World Class Scientists. ETST is extremely fortunate to have attracted world leaders to our executive leadership team and Board of Advisors. All of them are contributing their passion, time and expertise to the development of Cannabis Therapeutics unique cannabinoid-based products and solutions. Cannabis Therapeutics goal is to help advance the cannabis-cannabinoid healthcare industry and have a positive impact on the wellbeing of humans worldwide.”
Cannabis Therapeutics looks to discover and bring to market innovative solutions through its R&D, joint ventures and strategic partnerships by setting the highest quality standard in the cannabis-industrial hemp industry. Cannabis Therapeutics board of directors and upcoming new scientific advisory board intends to broaden the current operations of the Cannabis Therapeutics to include a variety of other products, solutions, laboratories and expertise, natural molecules, generic drugs, new compounds and new synthetic molecules, extraction and refinement of biomaterials, technologies and IP.
Cannabis Therapeutics, Inc will look to distinguish itself from many competing cannabinoid-focused biotechnology companies with its competent capital apportionment. While larger biotechnology companies spend millions and millions on clinical trials, Cannabis Therapeutics will look to very efficient with capital allocation in inventing & launching its Two (2) New Cannabinoid-based Pharmaceutical drugs which will be tested to treat roughly five (5) diseases with the help of its strategic partnerships.
Cannabis Therapeutics goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products. Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson's Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD) and Drug Addictions among other things.
Read More
Go $ETST $NMUS
$NMUS Cannabinoid Biotechnology Co, Watch!
$NMUS Cannabis Biotechnology Co, On Watch!
$NMUS Cannabis Biotechnology Co, On Watch!
$NMUS_IS_HEADED_WAY_UP!!!$1+__SOON_IN_MY_OPINION!!!
WE HAVE EXCLUSIVE ACCESS TO 49 YEARS WORTH OF CANNABIS FEDERAL RESEARCH ! NOT EVEN OUR COMPETITORS $GWPH, $ZYNE, $INSY, OR $CARA 's HAVE THIS TYPE OF RESEARCH AT THEIR DISPOSAL! BTW $ETST RECENTLY EXPLODED IN THE PAST COUPLE OF DAYS. THEY ARE A DIRECT COMPETITOR AND HAVE A MARKET CAP AT ALMOST 7X $NMUS AND THEY DONT EVEN HAVE THIS TYPE OF INTELLECTUAL PROPERTY!
WE OWN THE EXCLUSIVE RIGHTS!!
PER THE RECENT CEO INTERVIEW:
NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.